MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Amicus Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

5.97 -5.09

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.91

Max

6.29

Schlüsselkennzahlen

By Trading Economics

Einkommen

-36M

-22M

Verkäufe

-24M

125M

Gewinnspanne

-17.314

Angestellte

499

EBITDA

-27M

-4.8M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+154.37% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-349M

1.9B

Vorheriger Eröffnungskurs

11.06

Vorheriger Schlusskurs

5.97

Nachrichtenstimmung

By Acuity

37%

63%

119 / 376 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Amicus Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Juli 2025, 21:01 UTC

Ergebnisse

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

18. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

18. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

18. Juli 2025, 20:46 UTC

Ergebnisse

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18. Juli 2025, 20:39 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. Juli 2025, 20:36 UTC

Ergebnisse

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18. Juli 2025, 20:16 UTC

Akquisitionen, Fusionen, Übernahmen

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18. Juli 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. Juli 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18. Juli 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18. Juli 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18. Juli 2025, 18:24 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18. Juli 2025, 18:19 UTC

Ergebnisse

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18. Juli 2025, 18:11 UTC

Akquisitionen, Fusionen, Übernahmen

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18. Juli 2025, 18:11 UTC

Ergebnisse

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18. Juli 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18. Juli 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18. Juli 2025, 16:28 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. Juli 2025, 16:22 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Energy & Utilities Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

18. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. Juli 2025, 16:04 UTC

Ergebnisse

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18. Juli 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18. Juli 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18. Juli 2025, 15:47 UTC

Market Talk
Ergebnisse

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Peer-Vergleich

Kursveränderung

Amicus Therapeutics Inc Prognose

Kursziel

By TipRanks

154.37% Vorteil

12-Monats-Prognose

Durchschnitt 16 USD  154.37%

Hoch 22 USD

Tief 12 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Amicus Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

7

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

5.925 / 7.38Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

119 / 376 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.